217
Background:
Long-term endocrine therapy reduces recurrence in early-stage hormone receptor-positive breast cancer (BC) but may worsen comorbidities and survival. Understanding competing causes of mortality is essential for individualized treatment. We characterized cause-specific mortality and risk factor p...
C. Wabl, Morah Brown, Shi-Yun Zhu et al.· JCO Oncology Practice· 0 citations
Introduction We sought to characterize concordance of surveillance and treatment patterns in a large community-based healthcare system with the American Urologic Association/Society of Urologic Oncology (AUA/SUO) guideline for low- and intermediate-risk non-muscle invasive bladder cancer (NMIBC). We expect the results...
M. Shulman, V. Lee, J. Roh et al.· Bladder Cancer· 0 citations
BACKGROUND
Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone recep...
J. R. Ledesma, Joshua R. Nugent, R. Cheng et al.· JNCI Cancer Spectrum· 0 citations
Self-reported racial/ethnic discrimination in patient-provider interactions was associated with the non-initiation of hormonal therapy in women with breast cancer and the impact of this association on breast cancer prognosis.
Kevin R Bitsie, Thomas A. Pearson, M. Kwan et al.· Breast Cancer Research and T...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.